Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.verified

MRTX

Price:

$58.7

Market Cap:

$4.12B

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Thera...[Read more]

Industry

Biotechnology

IPO Date

2013-07-15

Stock Exchange

NASDAQ

Ticker

MRTX

The Current Ratio as of September 2024 (TTM) for Mirati Therapeutics, Inc. (MRTX) is 7.54

According to Mirati Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 7.54. This represents a change of 8.18% compared to the average of 6.97 of the last 4 quarters.

Mirati Therapeutics, Inc. (MRTX) Historical Current Ratio (quarterly & annually)

How has MRTX Current Ratio performed in the past?

The mean historical Current Ratio of Mirati Therapeutics, Inc. over the last ten years is 9.03. The current 7.54 Current Ratio has changed 8.25% with respect to the historical average. Over the past ten years (40 quarters), MRTX's Current Ratio was at its highest in in the December 2020 quarter at 19.64. The Current Ratio was at its lowest in in the June 2014 quarter at 1.10.

Quarterly (TTM)
Annual

Average

9.03

Median

8.67

Minimum

1.66

Maximum

19.64

Mirati Therapeutics, Inc. (MRTX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Mirati Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 264.28%

Maximum Annual Current Ratio = 19.64

Minimum Annual Increase = -77.45%

Minimum Annual Current Ratio = 1.66

Quarterly (TTM)
Annual
YearCurrent RatioChange
20226.96-33.74%
202110.50-46.55%
202019.64126.31%
20198.680.10%
20188.67-24.06%
201711.42187.57%
20163.97-68.98%
201512.80111.48%
20146.05264.28%
20131.66-77.45%

Mirati Therapeutics, Inc. (MRTX) Average Current Ratio

How has MRTX Current Ratio performed in the past?

The current Current Ratio of Mirati Therapeutics, Inc. (MRTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

12.36

5-year avg

10.89

10-year avg

9.03

Mirati Therapeutics, Inc. (MRTX) Current Ratio vs. Peers

How is MRTX’s Current Ratio compared to its peers?

Mirati Therapeutics, Inc.’s Current Ratio is greater than Reata Pharmaceuticals, Inc. (3.21), greater than Sarepta Therapeutics, Inc. (3.90), less than Krystal Biotech, Inc. (9.50), greater than Intercept Pharmaceuticals, Inc. (4.22), greater than Day One Biopharmaceuticals, Inc. (4.09), greater than Amylyx Pharmaceuticals, Inc. (4.66), less than Terns Pharmaceuticals, Inc. (21.02), greater than Apellis Pharmaceuticals, Inc. (5.08), less than Madrigal Pharmaceuticals, Inc. (0), less than Viking Therapeutics, Inc. (8.72), less than Hepion Pharmaceuticals, Inc. (37.69), greater than PTC Therapeutics, Inc. (5.62), greater than Akero Therapeutics, Inc. (2.23), less than null (24.89),

Build a custom stock screener for Mirati Therapeutics, Inc. (MRTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mirati Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Mirati Therapeutics, Inc. (MRTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Mirati Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Current Ratio?

How can you use the Current Ratio?

What is Mirati Therapeutics, Inc.'s Current Ratio?

How is the Current Ratio calculated for Mirati Therapeutics, Inc. (MRTX)?

What is the highest Current Ratio for Mirati Therapeutics, Inc. (MRTX)?

What is the 3-year average Current Ratio for Mirati Therapeutics, Inc. (MRTX)?

What is the 5-year average Current Ratio for Mirati Therapeutics, Inc. (MRTX)?

How does the current Current Ratio for Mirati Therapeutics, Inc. (MRTX) compare to its historical average?